My Watchlist

Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.

Recs

1

What You Need to Know About Biogen's Blockbuster

By | More Articles
October 20, 2012 | Comments (0)

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Today, Fool.com health-care analysts David Williamson and Max Macaluso look at what investors need to know about Biogen's potential blockbuster drug BG-12. 

It looks as if investors will have to wait a little longer, as the drug has been delayed. Shares are down only moderately on the news, and investors really shouldn't be too worried. David explains why this isn't as bad as it seems, and why this drug could still be one of the biggest blockbusters ever.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

David Williamson, Max Macaluso, and The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Biogen Idec. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

DocumentId: 2067182, ~/Articles/ArticleHandler.aspx, 5/25/2013 7:59:02 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 10 hours ago Sponsored by:
DOW 15,303.10 8.60 0.06%
S&P 500 1,649.60 -0.91 -0.06%
NASD 3,459.14 -0.28 -0.01%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/24/2013 4:02 PM
SNY $54.86 Up +0.30 +0.55%
Sanofi (ADR) CAPS Rating: ****
TEVA $39.34 Down -0.15 -0.38%
Teva Pharmaceutica… CAPS Rating: *****
NVS $74.36 Up +0.54 +0.73%
Novartis CAPS Rating: ****
ABT $37.76 Up +0.28 +0.75%
Abbott Laboratorie… CAPS Rating: *****
BIIB $235.24 Up +2.62 +1.13%
Biogen Idec CAPS Rating: ****

Advertisement